001     282968
005     20260217131429.0
024 7 _ |2 doi
|a 10.1038/s41531-025-01232-4
024 7 _ |2 pmid
|a pmid:41361244
024 7 _ |2 pmc
|a pmc:PMC12689644
037 _ _ |a DZNE-2025-01420
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Hähnel, Tom
|b 0
245 _ _ |a Brain age gap as predictor of disease progression in Parkinson's disease.
260 _ _ |a [London]
|b Springer Nature
|c 2025
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1766153431_31933
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a Parkinson's disease (PD) exhibits high heterogeneity in disease progression, complicating management and increasing required sample sizes for clinical trials. This study evaluates Brain Age Gap (BAG)-the difference between brain age and chronological age-for predicting disease progression in PD. Structural MRI-derived gray matter volumes were analyzed for 451 early-stage PD patients and 172 healthy controls from the PPMI cohort. PD patients had a baseline BAG of 1.1 years, with fast-progressing patients exhibiting a BAG of 3.0 years, whereas slow-progressing patients resembled the BAG of healthy controls. Higher BAG was associated with more severe baseline symptoms, faster cognitive decline in several domains, increased hazard of developing mild cognitive impairment, and faster progression of dopaminergic neuron loss in longitudinal DaTSCANs. BAG-based patient stratification could reduce sample sizes of randomized clinical trials by 23-58%. These findings suggest BAG as a prognostic biomarker of disease progression, which may accelerate the development of disease-modifying treatments.
536 _ _ |0 G:(DE-HGF)POF4-353
|a 353 - Clinical and Health Care Research (POF4-353)
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
700 1 _ |a More, Shammi
|b 1
700 1 _ |a Hoffstaedter, Felix
|b 2
700 1 _ |a Patil, Kaustubh R
|b 3
700 1 _ |a Fröhlich, Holger
|b 4
700 1 _ |0 P:(DE-2719)2814178
|a Falkenburger, Björn H
|b 5
|e Last author
|u dzne
773 _ _ |0 PERI:(DE-600)2819218-7
|a 10.1038/s41531-025-01232-4
|g Vol. 11, no. 1, p. 353
|n 1
|p 353
|t npj Parkinson's Disease
|v 11
|x 2373-8057
|y 2025
856 4 _ |u https://pub.dzne.de/record/282968/files/DZNE-2025-1420.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/282968/files/DZNE-2025-1420.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:282968
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |0 I:(DE-588)1065079516
|6 P:(DE-2719)2814178
|a Deutsches Zentrum für Neurodegenerative Erkrankungen
|b 5
|k DZNE
913 1 _ |0 G:(DE-HGF)POF4-353
|1 G:(DE-HGF)POF4-350
|2 G:(DE-HGF)POF4-300
|3 G:(DE-HGF)POF4
|4 G:(DE-HGF)POF
|a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
|d 2024-12-11
915 _ _ |0 StatID:(DE-HGF)0160
|2 StatID
|a DBCoverage
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |0 StatID:(DE-HGF)1030
|2 StatID
|a DBCoverage
|b Current Contents - Life Sciences
|d 2024-12-11
915 _ _ |0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
|a Creative Commons Attribution CC BY 4.0
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b NPJ PARKINSONS DIS : 2022
|d 2024-12-11
915 _ _ |0 StatID:(DE-HGF)0501
|2 StatID
|a DBCoverage
|b DOAJ Seal
|d 2024-04-10T15:43:48Z
915 _ _ |0 StatID:(DE-HGF)0500
|2 StatID
|a DBCoverage
|b DOAJ
|d 2024-04-10T15:43:48Z
915 _ _ |0 StatID:(DE-HGF)0113
|2 StatID
|a WoS
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |0 StatID:(DE-HGF)0700
|2 StatID
|a Fees
|d 2024-12-11
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |0 StatID:(DE-HGF)0510
|2 StatID
|a OpenAccess
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:43:48Z
915 _ _ |0 StatID:(DE-HGF)0561
|2 StatID
|a Article Processing Charges
|d 2024-12-11
915 _ _ |0 StatID:(DE-HGF)9905
|2 StatID
|a IF >= 5
|b NPJ PARKINSONS DIS : 2022
|d 2024-12-11
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2024-12-11
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
|d 2024-12-11
920 1 _ |0 I:(DE-2719)1710012
|k AG Falkenburger
|l Translational Parkinson Research
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1710012
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21